The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial.
about
Use of Inotropic Agents in Treatment of Systolic Heart FailureSignaling effectors underlying pathologic growth and remodeling of the heartForce generation by kinesin and myosin cytoskeletal motor proteinsUnderstanding cardiomyopathy phenotypes based on the functional impact of mutations in the myosin motorRecommendations on pre-hospital and early hospital management of acute heart failure: a consensus paper from the Heart Failure Association of the European Society of Cardiology, the European Society of Emergency Medicine and the Society of AcademicTargeting myocardial remodelling to develop novel therapies for heart failure: a position paper from the Working Group on Myocardial Function of the European Society of CardiologyManagement of the cardiorenal syndrome in decompensated heart failureChallenges in acute heart failure clinical management: optimizing care despite incomplete evidence and imperfect drugsTargeting the sarcomere to correct muscle functionPotential new drug treatments for congestive heart failure.Thin filament incorporation of an engineered cardiac troponin C variant (L48Q) enhances contractility in intact cardiomyocytes from healthy and infarcted hearts.Translation of Cardiac Myosin Activation with 2-deoxy-ATP to Treat Heart Failure via an Experimental Ribonucleotide Reductase-Based Gene TherapyInfluence of metabolic dysfunction on cardiac mechanics in decompensated hypertrophy and heart failure.Nitroxyl (HNO): A novel approach for the acute treatment of heart failureAnalytical comparison of natural and pharmaceutical ventricular myosin activatorsModulating Beta-Cardiac Myosin Function at the Molecular and Tissue Levels.2-Deoxy adenosine triphosphate improves contraction in human end-stage heart failure.Preserved cardiac function despite marked impairment of cAMP generation.Acute decompensated heart failure update.Cardiac myosin binding protein-C: redefining its structure and function.The novel cardiac myosin activator omecamtiv mecarbil increases the calcium sensitivity of force production in isolated cardiomyocytes and skeletal muscle fibres of the ratRelative bioavailability, food effect, and safety of the single-dose pharmacokinetics of omecamtiv mecarbil following administration of different modified-release formulations in healthy subjectsPharmacological Strategies to Retard Cardiovascular AgingTreating volume overload in acutely decompensated heart failure: established and novel therapeutic approachesIncorporating development of a patient-reported outcome instrument in a clinical drug development program: examples from a heart failure program.Pathological ventricular remodeling: therapies: part 2 of 2.Cardiac resynchronization sensitizes the sarcomere to calcium by reactivating GSK-3β.Worse prognosis of real-world patients with acute heart failure from the Czech AHEAD registry in comparison to patients from the RELAX-AHF trial.Expert consensus document: Mitochondrial function as a therapeutic target in heart failureHypertrophic and dilated cardiomyopathy: four decades of basic research on muscle lead to potential therapeutic approaches to these devastating genetic diseases.Heart failure in 2011: Heart failure therapy--technology to the fore.Developments in heart failure 2011.Heavy and light roles: myosin in the morphogenesis of the heart.Inotropes for the management of acute heart failure patients with renal dysfunction. Still an option?Novel pharmacologic therapies in development for acute decompensated heart failure.Causes and treatment of oedema in patients with heart failure.Molecular targets of current and prospective heart failure therapies.Pharmacological treatment of acute heart failure: current treatment and new targets.What's new in the treatment of acute heart failure?Antagonist molecules in the treatment of angina
P2860
Q26774435-F3B35D4C-0CC2-46F7-A82F-D529BF99CE9FQ26825154-1E7A89B3-66C9-453B-B1A3-7FF90E012ECAQ26827691-B333B1D3-F2D3-4434-84F2-BDB24A99F569Q26996693-7021ACAC-5A20-47C9-93EC-56583D389D2FQ27008175-79A77855-910B-44E5-8A24-F2E90393C51BQ27024879-12E8EF76-0928-4C2D-8EF7-7F6F730C1838Q27028203-98A631D4-F6F3-48D9-9B48-5E0B4EE41DF7Q28085736-B59E1206-9A4D-4C12-879D-2796AC226225Q28260629-DF70C3C7-6056-4385-814D-4F85FAAAA03BQ30251531-5141AF78-8BBD-4173-B4E4-298E90D5921BQ30582828-89E0E47B-EC4C-448B-84D6-74E8DC3E79F5Q33728779-270B641B-A618-4E20-96A9-79725B98888AQ33894414-475C41B9-AEE7-4ECB-B4CB-EFB8571AC59AQ33946688-E9FBACED-A125-4702-B4EF-3302E1EBFBF1Q34070160-B6A38DD1-4BE7-411E-ACF7-478D9F8D3C99Q34549974-6195589A-9358-418B-BBDB-5889DDBF8A04Q34995668-D5F5F445-0E90-4680-BCCB-2E5C3415FFF4Q35023632-E3446176-2C2B-458A-8FAE-CF98115E5226Q35139964-576652D3-B6E9-4A0E-B6F6-79BEC8AD35CCQ36030150-65F7475E-2CCC-4C63-A354-3F0544050BB6Q36036237-9B26E6AB-AC75-4F82-BA8D-C90A891E31BFQ36645693-926A95AA-0E88-4024-A250-08D567E8FCF4Q36972415-01F003D9-8667-4128-9492-73B78D7CD7DFQ37140940-B82F7E3A-0A2F-41E8-B598-B2857E1C3881Q37258267-16996BB3-88B3-450D-8BDF-55528765E07DQ37312758-D95B460C-EFF4-4786-A962-5A57D6FAE7C8Q37410579-B0B7819C-B68B-45FD-B488-495949264E62Q37625576-A3F85EA9-858A-40D1-B7B1-C7D1ED4299B3Q37699474-7D23BA61-DBFB-48C7-A4CB-5FC069AFC4F4Q37701056-6C0E4FB1-9C1B-4FC7-8AC3-BB94C6377A5AQ37978448-8D260E90-B4BC-4615-AE20-4D8BBD4967B0Q37995246-C9393DE9-D773-4474-94D6-9B104A58D171Q38041426-CD5A19EB-D8E2-4BF6-9BD6-93D022B2C954Q38061473-808A48AD-96DE-497D-83ED-D0C311CDCE91Q38073647-367C439E-B1E9-4126-85C4-DA0897F8B9EFQ38074093-B0CBF536-2EED-4DCB-9B21-F60901D88D19Q38076688-729B0775-1CBB-4E7D-9190-78DF049E0326Q38122297-8113DC78-4F69-4AC9-9045-3D2A2E69DD69Q38123740-629127B1-2F41-41E5-8ABB-EDFDE82E4624Q38139089-49642DFF-F946-4F06-B1E5-541E2450B349
P2860
The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial.
description
2011 nî lūn-bûn
@nan
2011 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
The effects of the cardiac myo ...... r, dose-ranging phase 2 trial.
@ast
The effects of the cardiac myo ...... r, dose-ranging phase 2 trial.
@en
The effects of the cardiac myo ...... r, dose-ranging phase 2 trial.
@nl
type
label
The effects of the cardiac myo ...... r, dose-ranging phase 2 trial.
@ast
The effects of the cardiac myo ...... r, dose-ranging phase 2 trial.
@en
The effects of the cardiac myo ...... r, dose-ranging phase 2 trial.
@nl
prefLabel
The effects of the cardiac myo ...... r, dose-ranging phase 2 trial.
@ast
The effects of the cardiac myo ...... r, dose-ranging phase 2 trial.
@en
The effects of the cardiac myo ...... r, dose-ranging phase 2 trial.
@nl
P2093
P50
P921
P1433
P1476
The effects of the cardiac myo ...... er, dose-ranging phase 2 trial
@en
P2093
Andrew A Wolff
Barry H Greenberg
Cyril P Clarke
Darrel P Francis
Evgeny M Nifontov
Fady I Malik
Jacqueline H Lee
Jamil Mayet
John R Teerlink
Jonathan H Goldman
P304
P356
10.1016/S0140-6736(11)61126-4
P407
P577
2011-08-01T00:00:00Z